Xtant Medical stock draws a USD 1.00 target from Lucid Capital

Xtant Medical stock stood at USD 0.38 on the NYSE American on September 24, 2026, while Lucid Capital Markets initiated coverage with a Buy rating and a USD 1.00 price target on September 2, 2026, according to Investing.com. The rating arrived as the medical-device company works to broaden distribution of its regenerative medicine products.

Analyst target contrasts with results

Lucid Capital Markets highlighted Xtant's in-house production across five orthobiologics categories, including demineralized bone matrix, allograft, cellular allograft, synthetic bone graft and growth factor products, Investing.com reported on September 2, 2026. The USD 1.00 target is USD 0.62 above the September 24 price, equivalent to 163.16 percent above that price.

The latest quarterly figures point in the opposite direction operationally. For the quarter ended June 30, 2026, revenue declined 35 percent year over year to USD 23.0 million, gross margin narrowed to 57.9 percent, and the company posted a USD 9.4 million net loss versus a USD 3.6 million profit in the prior-year quarter, according to TS2. Adjusted EBITDA was negative USD 2.7 million compared with positive USD 6.9 million a year earlier.

BioHorizons opens a dental channel

On August 27, 2026, Xtant announced an exclusive partnership under which BioHorizons will distribute its allogeneic growth factor technology as Prolifica through its commercial network in the United States and Canada, StockTitan reported. The product is based on Xtant's OsteoFactor Pro technology and targets dental and oral-maxillofacial procedures.

The partnership gives Xtant access to BioHorizons' commercial network while adding a channel outside its established spinal and orthopedic markets. Its financial importance will depend on adoption, because second-quarter revenue was USD 23.0 million and the 2026 revenue outlook was reduced to USD 99 million to USD 103 million, according to TS2.

Small-cap valuation stays data dependent

Xtant Medical had a market capitalization of USD 52,865,110 and volume of 72,748 shares on September 24, 2026. Its 52-week range was USD 0.27 to USD 0.95, placing the latest price USD 0.57 below the high and USD 0.11 above the low.

The figures frame the investment case clearly: the BioHorizons channel expands commercial reach, while the latest quarter shows falling revenue, negative adjusted EBITDA and a lower full-year outlook. The analyst target therefore depends on execution improving from the June 30, 2026 operating base.

Stock trades at USD 0.38

Xtant Medical stock stood at USD 0.38 on the NYSE American on September 24, 2026. The latest quote was supported by a market capitalization of USD 52,865,110.